{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.285777","statisticalComment":"stratified","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.653","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.265","estimateComment":"regorafenib over control. 58 (87.9%) patients in placebo group and 91 (68.4%) patients in regorafenib had started open-label treatment with regorafenib before time of final database cutoff 08 Jun 2015.","groupDescription":"Hazard ratio and its 95% CI was based on stratified Cox Regression Model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.909","statisticalComment":"stratified","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0"},{"groupId":"OG001","value":"80.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Median OS was not observed at the time of PFS analysis and first analysis of OS, therefore only the proportion of death events was reported in the results posting system. This approach was maintained for the subsequent updates in the results posting system.","groups":[{"description":"Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG000","title":"Regorafenib (Stivarga, BAY73-4506)"},{"description":"Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS). 58 (87.9%) patients in placebo group and 91 (68.4%) patients in regorafenib had started open-label treatment with regorafenib before time of final database cutoff 08 Jun 2015","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until date of database cutoff (08 Jun 2015)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Percentage of patients with death"}